for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Smith & Nephew plc

SN.L

Latest Trade

1,670.50GBp

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1,376.00

 - 

1,998.40

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Latest Developments

Smith & Nephew Sees Annual Underlying Revenue Growth Of 3.5% To 4.5%

Oct 31 (Reuters) - Smith & Nephew PLC <SN.L>::SMITH & NEPHEW PLC - TRADING STATEMENT.SMITH & NEPHEW PLC - Q3 REVENUE UP 4.0% ON AN UNDERLYING BASIS; REPORTED GROWTH WAS 6.5%.SMITH & NEPHEW PLC - UNDERLYING REVENUE GROWTH EXPECTED TO BE IN RANGE 3.5% TO 4.5% IN FULL YEAR.SMITH & NEPHEW PLC - FY TRADING PROFIT MARGIN EXPECTED TO BE AROUND 22.8%.SMITH & NEPHEW PLC - 390BPS BENEFIT OF ACQUISITIONS OUTWEIGHED 140BPS CURRENCY HEADWIND IN QUARTER.SMITH & NEPHEW PLC - CONTINUED MID-TEENS GROWTH FROM EMERGING MARKETS, LED BY ANOTHER QUARTER OF STRONG GROWTH IN CHINA.SMITH & NEPHEW PLC - SPORTS MEDICINE & ENT ACCELERATED FROM STRONG FIRST HALF, DELIVERING 6.9% REVENUE GROWTH IN QUARTER.

Smith+Nephew Says Namal Nawana To Step Down As CEO

Oct 21 (Reuters) - Smith+Nephew <SN.L>::DIRECTORATE CHANGE.NAMAL NAWANA WILL STEP DOWN FROM BOARD AND HIS POSITION AS CHIEF EXECUTIVE OFFICER .ROLAND DIGGELMANN HAS BEEN APPOINTED AS COMPANY'S NEW CEO.ROLAND DIGGELMANN WILL TAKE ON HIS NEW RESPONSIBILITIES ON 1 NOVEMBER 2019.

Smith & Nephew Says FY Underlying Revenue Growth Guidance Range Raised 50 BPS To 3.0% To 4.0%

July 31 (Reuters) - Smith & Nephew PLC <SN.L>::H1 REVENUE ROSE 3.9 PERCENT TO 2.485 BILLION USD.HALF-YEAR REPORT.FULL YEAR REVENUE GUIDANCE UPGRADED.FULL YEAR REVENUE GUIDANCE UPGRADED.Q2 REVENUE UP 3.5% ON AN UNDERLYING BASIS; REPORTED GROWTH WAS 3.1% DESPITE IMPACT OF A 2.9% CURRENCY HEADWIND.STRONG MID-TEENS GROWTH FROM EMERGING MARKETS, LED BY CHINA UP MORE THAN 30% IN QUARTER.EXPECTED FY UNDERLYING REVENUE GROWTH GUIDANCE RANGE RAISED 50BPS TO 3.0% TO 4.0%.QTRLY REVENUE $1,283 MILLION VERSUS $1,245 MILLION.HY TRADING EPS/ EPSA 45.8 CENTS.STRONG PERFORMANCE IN EMERGING MARKETS AND GLOBAL SPORTS MEDICINE.EMERGING MARKETS NOW ACCOUNT FOR 19% OF ALL SALES.INTERIM DIVIDEND FOR FIRST HALF OF 2019 IS 14.4¢ PER SHARE (28.8¢ PER ADS).

Smith & Nephew Launches Conquest FN Femoral Neck Fracture System

June 5 (Reuters) - Smith & Nephew PLC <SN.L>::SMITH & NEPHEW LAUNCHES CONQUEST FN™ FEMORAL NECK FRACTURE SYSTEM.

Smith & Nephew's Q1 Revenue Rises To $1.2 Bln

May 2 (Reuters) - Smith & Nephew Plc <SN.L>::Q1 REVENUE ROSE 4.4 PERCENT TO 1.202 BILLION USD.Q1 REVENUE OF $1,202 million (2018: $1,196 MILLION), UP 4.4 PCT ON AN UNDERLYING BASIS (0.5 PCT REPORTED GROWTH AFTER -3.9 PCT FOREIGN EXCHANGE HEADWIND).2019 GUIDANCE UPDATED.INCREASINGLY CONFIDENT THAT 2019 UNDERLYING REVENUE GROWTH WILL BE IN UPPER HALF OF GUIDANCE RANGE OF 2.5 PCT TO 3.5 PCT.EXPECTED TRADING PROFIT MARGIN UNCHANGED IN RANGE OF 22.8 PCT TO 23.2 PCT.2019 GUIDANCE IS FOR YEAR-ON-YEAR IMPROVEMENT IN UNDERLYING REVENUE GROWTH AND TRADING PROFIT MARGIN.CONTINUE TO EXPECT 2019 TRADING PROFIT MARGIN TO BE IN RANGE OF 22.8 PCT TO 23.2 PCT.2019 REPORTED REVENUE GROWTH RATE IS EXPECTED TO BE IN RANGE OF 2.9 PCT TO 3.9 PCT.

Smith & Nephew Completes Acquisition Of Leaf Healthcare

April 17 (Reuters) - Smith & Nephew PLC <SN.L>::SMITH & NEPHEW PLC - ACQUISITION.SMITH & NEPHEW PLC - COMPLETED ACQUISITION OF LEAF HEALTHCAR.

Smith & Nephew Acquires Leaf Healthcare For Undisclosed Sum

April 1 (Reuters) - Smith & Nephew PLC <SN.L>::SMITH & NEPHEW PLC - ACQUISITION OF LEAF HEALTHCARE, INC..SMITH & NEPHEW PLC - COMMERCIAL TERMS HAVE NOT BEEN DISCLOSED..SMITH & NEPHEW - TO BUY LEAF HEALTHCARE, DEVELOPER OF LEAF PATIENT MONITORING SYSTEM FOR PRESSURE INJURY PREVENTION, PATIENT MOBILITY MONITORING.SMITH & NEPHEW PLC - TRANSACTION WILL BE FINANCED FROM EXISTING CASH AND DEBT FACILITIES.

Smith & Nephew Acquires Brainlab Orthopaedic Joint Reconstruction Business

Smith & Nephew PLC <SN.L>::SMITH & NEPHEW ACQUIRES BRAINLAB ORTHOPAEDIC JOINT RECONSTRUCTION BUSINESS.SMITH & NEPHEW PLC - TRANSACTION INCLUDES CERTAIN INTANGIBLE ASSETS AS WELL AS ORTHOPAEDIC BRAINLAB SALESFORCE.SMITH & NEPHEW PLC - CO, BRAINLAB WILL COLLABORATE IN DEVELOPING APPLICATIONS IN ORTHOPAEDIC RECONSTRUCTION AND SPORTS MEDICINE.

Osiris Therapeutics Says Co To Pay $18.7 Mln Termination Fee, If Deal Is Terminated - SEC Filing

March 12 (Reuters) - Osiris Therapeutics Inc <OSIR.O>::OSIRIS THERAPEUTICS INC - IF DEAL IS TERMINATED UNDER CERTAIN CIRCUMSTANCES CO TO PAY $18.7 MILLION TERMINATION FEE - SEC FILING.

Smith & Nephew To Buy Osiris Therapeutics For $660 Mln

March 12 (Reuters) - Smith & Nephew PLC <SN.L>::SMITH & NEPHEW TO ACQUIRE OSIRIS THERAPEUTICS, INC.PROPOSED DEAL FOR $19.00 PER SHARE IN CASH.DEAL FOR A TOTAL EQUITY VALUE OF APPROXIMATELY $660 MLN.OSIRIS' 360 EMPLOYEES ARE EXPECTED TO JOIN SMITH & NEPHEW ON COMPLETION.ACQUISITION WILL BE FINANCED FROM SMITH & NEPHEW'S EXISTING CASH AND DEBT FACILITIES.TRANSACTION IS EXPECTED TO BE ACCRETIVE TO SMITH & NEPHEW'S ADJUSTED EARNINGS PER SHARE FROM 2020.ACQUISITION IS EXPECTED TO GENERATE RETURN ON INVESTED CAPITAL THAT EXCEEDS CO'S COST OF CAPITAL IN THIRD YEAR AFTER CLOSING.PETER FRIEDLI TO COMMIT TO TENDER ABOUT 30% OUTSTANDING SHARES OF OSIRIS IN FAVOUR OF DEAL.UNDER TERMS OF DEAL, WILL COMMENCE 2-STEP TENDER OFFER TO PURCHASE ALL OUTSTANDING SHARES OF OSIRIS COMMON STOCK FOR $19/SHR IN CASH.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up